10/19/12. Depression and Inflammation: The Interplay With Autoimmune Disease. Charles B. Nemeroff, MD, PhD
|
|
- Lorin Flynn
- 5 years ago
- Views:
Transcription
1 1/19/12 Depression and Inflammation: The Interplay With Autoimmune Disease Charles B. Nemeroff, MD, PhD Leonard M. Miller School of Medicine University of Miami Miami, FL Charles B. Nemeroff, MD, PhD Disclosures Research/Grants: Agency for Healthcare Research and Quality (AHRQ); National Institutes of Health (NIH) Consultant: Eli Lilly and Company; Shire Pharmaceuticals Inc.; SK Pharma; Roche; Takeda Pharmaceuticals North America, Inc.; Xhale, Inc. Stockholder: CeNeRx BioPharma; NovaDel Pharma, Inc.; PharmaNeuroBoost, Revaax Pharmaceuticals LLC; Xhale, Inc. Other Financial Interest: CeNeRx BioPharma; PharmaNeuroBoost Patents: Method and devices for transdermal delivery of lithium (US 6,375,99B1) Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,27B2) Scientific Advisory Boards: American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); CeNeRx BioPharma; National Alliance for Research on Schizophrenia and Depression (NARSAD); PharmaNeuroBoost; Xhale, Inc.; Skyland Trail; AstraZeneca Pharmaceuticals (29) Board of Directors: American Foundation for Suicide Prevention (AFSP); Gratitude America; Mt. Cook Pharma. Inc. (21); NovaDel Pharma, Inc. (211); Skyland Trail 1
2 1/19/12 Learning Objective Recognize the interplay of inflammation and depression and use this knowledge to accurately and consistently assess patients with inflammatory disease for depression Proinflammatory Cytokines Play a Central Role in Classic Autoimmune Conditions Rheumatoid arthritis Inflammatory bowel disease Multiple sclerosis Psoriasis Ankylosing spondylitis But also: Coronary artery disease Diabetes and the metabolic syndrome Cancer Alzheimer s disease Major Clinical Disorders Associated with Inflammation Cardiovascular disease Inflammatory markers (CRP/IL-6) are potent predictors of disease outcome; involvement of inflammation in plaque formation and cardiac irritability Diabetes/metabolic syndrome/obesity High correlation between insulin resistance and IL-6 and other inflammatory markers Cancer Activation of inflammatory signaling pathways (e.g., NF-kB) implicated as a fundamental mechanism of carcinogenesis and chemotherapy resistance 2
3 Stress, Depression Endocrine System Depression/ Sickness Behavior CNS IMMUNE SYSTEM Immune- Based Diseases Cytokines (e.g. IFN-alpha, IL-1, IL-6, TNF-alpha) Inflammation/ Immune Activation (e.g. secondary to infection, trauma, surgery, radiation, chemotherapy, stress, etc.) Miller AH, et al. Biol Psychiatry. 29;65(9): Major Depressive Disorder and Systemic Illnesses Patients with MDD have a doubling of mortality and coronary artery disease at any age, independent of smoking, hypertension, and other risk factors for poor health 1 2% to 25% premenopausal patients with MDD have premature osteopenia and osteoporosis MDD is associated with an ~ 2-fold increase in the risk for Type II diabetes Is Major Depressive Disorder a Pro-Inflammatory State? 1. Wulsin LR. Harv Rev Psychiatry. 24;12(2): PMID:
4 Endothelial cell Innate Immunity/Inflammation Leukocyte Diapedesis Chemokines Stromal cell Adhesion molecules Local Local Effects - Increased vascular permeability - Vasodilation - Chemokine production - Expression of adhesion molecules - Pain tumor rubor calor dolor Macrophage NF-κB TNF, IL-1, IL-6 IFN-alpha Pathogen (e.g. bacteria), Cellular Debris Toll-like TNF receptors IL-1 (TLRs) IL-6 IFN-alpha Systemic Effects on Liver Acute Phase Response - C-reactive protein - Serum amyloid A - Haptoglobin - Alpha 1-antichymotrypsin Effects on Brain - Fever - Fatigue - Anorexia - Anhedonia - Altered sleep sickness behavior/ depression Conservation of energy resources to promote increased metabolic demands of fighting infection and mounting a fever Basis for the Hypothesis that Inflammation and an Activated Innate Immune Response May Play a Role in Depression Patients with depression (both medically ill and medically healthy) have been found to exhibit all the cardinal features of inflammation Increased plasma and CSF concentrations of innate immune cytokines (IL-6 most reliable) Increased acute phase reactants (CRP most reliable) Increased chemokines Increased cellular adhesion molecules In the majority of studies, inflammatory markers decrease with successful antidepressant therapy ( state marker ) Depressed patients with increased inflammatory markers are more likely to be treatment resistant In our study, 2/3 with high inflammation according to CDC/AHA guidelines with CRP > 3mg/L - ~5 million depressed individuals in US 1/3 with CRP > 5mg/L ~3 million depressed individuals in US Depression is Associated with Elevated Body Temperature in Medically Healthy Patients 37.6 Depression No Depression Temp ( o C) : AM 3: PM 11: PM 6: AM Time Szuba, et al. Biol Psychiatry
5 IL-6 Concentrations In Patients With Depression And Cancer Plasma IL-6 Concentration (pg/ml) Healthy Controls (n = 1) Depressed Controls (n = 12) Study Group Cancer Patients (n = 13) Depressed CA Patients with highest IL-6 plasma concentrations (H = 13.9, df = 3, p =.3) Musselman DL, et al. Am J Psychiatry. 21:158(8): Depressed Cancer Patients (n = 8) Basis for the Hypothesis that Inflammation May Play a Role in Depression Positive correlation between depressive symptom severity and innate immune cytokines Elevated innate immune cytokines predict poor response to antidepressant therapies and are elevated in patients with treatment resistance. Cytokine gene polymorphisms (IL-1, TNF) predict antidepressant treatment response Administration of innate immune cytokines, especially IL-1, TNF-alpha, and IL-6, as well as IFN-alpha, produce behavioral changes in laboratory animals and humans that resemble major depression Inhibition of cytokine signaling has been found to alleviate depressive and anxiety behaviors in patients with inflammatory disorders and in laboratory animals Basis for the Hypothesis that Proinflammatory Cytokines Play a Role in Depression and Depressive Symptoms Cytokines released peripherally have access to the brain Passage through leaky regions in the BBB Active transport Transmission through afferent nerve fibers (vagus) There is a cytokine network in the CNS Glia (microglia) and neurons express/produce cytokines and express cytokine receptors Cytokines have effects on neurotransmitter turnover, neuroendocrine function, and behavior (sickness behavior) 5
6 Childhood Abuse = Unhealed Wounds More Psychological Problems (such as depression anxiety, somatization, low self esteem, substance abuse, suicide attempts) Women who experienced no abuse Women who experienced childhood abuse = Women experiencing current abuse Women who have experienced childhood abuse and are experiencing current abuse Physical Symptoms Less (such as back pain, headaches, pelvic pain, abdominal symptoms, etc.) McCauley J, et al. JAMA. 1997;277(17): PMID: More Chronic Pelvic Pain, Fatigue, and Physical Symptoms Acyclic Chronic Pelvic Pain Loss of Energy/ Fatigue General Health Checklist Prevalence of CPP (%) Prevalence of Fatigue (%) Controls ELS ELS/PTSD General Dermatological Visual Audio/Olfactoric MTN Cardiological Endocrinological Orthopedical Gastrointestinal Neurological OB-GYN/Urological Controls ELS ELS/PTSD Controls ELS ELS/PTSD Dotted bar: Loss of energy Filled bar: Tired all the time Number of Symptoms in the Past Month Patients with Major Depression Exhibit an Exaggerated Inflammatory Response to Stress A Possible Link Between Stress, Depression, and Illness Plasma IL-6, pg/ ml 6 5 Control (n = 13) Major Depression (n = 14) Control (n = 13) Major Depression + (n = 14) Plasma IL-6, pg/ ml NF-kB DNA-binding (% of baseline) Control (n = 16) Major Depression (n = 1) TSST Time (Min) TSST TSST Time (Min) Between group comparison, p < Between.5 group comparison, p <.5 + Within group comparison vs. +Within min time group pt, comparison p <.5 vs. min time pt, p <.5 The majority of the depressed patients in this sample also endorsed significant early life stress as measured by the CTQ Pace, et al. Am J Psychiatry. 26;163(9): PMID:
7 Childhood Maltreatment Predicts Adult Inflammation in a Life-Course Study The life-course association between childhood maltreatment and adult inflammation was examined in a birth cohort followed to age 32 years as part of the Dunedin Multidisciplinary Health and Development Study Maltreated children showed a significant and graded increase in the risk for clinically relevant C-reactive protein levels, 2 years later The association between maltreatment and adult inflammation also generalizes to fibrinogen and white blood cell count Childhood maltreatment is a previously undescribed, independent, and preventable risk factor for inflammation in adulthood Danese A, et al. Proc Natl Acad Sci USA. 27;14(4): PMID: The Association of Childhood Maltreatment with Biomarkers of Inflammation Danese A, et al. Proc Natl Acad Sci U S A. 27;14(4): PMID: Questions Do proinflammatory cytokines, and therefore, the immune system contribute to the pathophysiology of major depression in the medically ill? What mechanisms are involved? What are the treatment implications? 7
8 Interferon-Alpha as a Model System to Study Cytokine- Induced Depression Antiviral/antiproliferative cytokine used to treat viral infections and cancer Potent inducer of innate immune response including innate immune cytokines (especially IL-6) Potent inducer of behavioral toxicity including symptoms of major depression in humans and non-human primates IFN-Alpha-Induced Behavioral Symptoms in Patients with Malignant Melanoma Placebo-treated patients (%) experiencing moderate-to-severe intensity in the listed symptom during IFNalpha therapy Capuron L, et al. Neuropsychopharmacology. 22;26(5): PMID: High-Dose Interferon in Malignant Melanoma Paroxetine Pretreatment Randomized, Double-Blind Treatment (N = 4) Paroxetine x 2 Weeks Placebo x 2 Weeks IV IFN-α x 4 Weeks 2 x 1 6 U/m 2 SQ IFN-α up to 48 Weeks 1 x 1 6 U/m 2 Paroxetine Arm 2-4 mg Placebo Arm Week Week 4 Week 8 Week 12 Musselman DL, et al. N Engl J Med. 21;344(13): PMID:
9 Incidence of Major Depression During the First 12 weeks of IFN-alpha 1 Survival Free of Major Depression (%) n = Weeks on IFN-alpha Musselman DL, et al. N Engl J Med. 21;344(13): PMID: Paroxetine Pre-treatment Reduces the Incidence of Major Depression During the First 12 weeks of High Dose IFN-alpha for Malignant Melanoma 1 Survival Free of Major Depression (%) Paroxetine (n = 18) Placebo (n = 2) Weeks on IFN-alpha Musselman DL, et al. N Engl J Med. 21;344(13): PMID: IFN-alpha-induced Depression is Associated with Tryptophan (TRP) Depletion TRP IFN-alpha/ Cytokines ACTH IDO Kynurenine Quinolinic Acid CRH Serotonin IDO indolamine 2,3 dioxygenase Capuron L, et al. Mol Psychiatry. 22;7: PMID: IFN-alpha-induced Depression is Associated with Exaggerated HPA Activation Depression/ Sickness Behavior Adrenal Gland Cortisol IFN-alpha/ cytokines Capuron L, et al. Am J Psychiatry. 23;16: PMID:
10 IFN-alpha-induced Depressive-like Behavior ( Huddling ) is Associated with Exaggerated HPA Activation in Monkeys 25 2 Taken from Kalin,, N.H., 1985 [12] ICV CRH sc IFN-alpha (2 million units/m 2 ) Huddling: a fetal-like self-enclosed position with head at or below shoulders. ACTH (pg/ml) p <.1 Non- Huddler Huddler Maximal ACTH response to IFN-alpha in huddlers vs. non-huddlers McKinney WT Jr., et al. Dis Nerv Syst. 1971;32(11): PMID: Kalin NH, et al. Life Sci. 1985;36(12): PMID: IFN-alpha Effects on Basal Ganglia Function Correlate with Fatigue Capuron L, et al. Neuropsychopharmacology. 27;32(11): PMID: CSF Homovanillic Acid (HVA), the Major Metabolite of Dopamine, Correlates with Fatigue and CSF IL-6 in IFN-alpha-treated Patients 1 r = -.43, p <.5 1 r = -.43, p < CSF HVA (ng/ml) CSF HVA (ng/ml) CSF IL-6 (pg/ml) Fatigue (Total Score) IFN-alpha IL-6 dopamine HVA fatigue 1
11 Prevalence of Moderate/ Severe Depressive Symptoms During Treatment with Pegylated IFN-alpha % of Patients with SDS Index Exponential Trend Line p <.1 (Cochran-Armitage Trend Test) Baseline Week 4 Week 8 Week 12 Week 24 Significantly different from baseline (p <.5) Raison CL, et al. J Clin Psychiatry. 25;66(1): PMID: Rates of Depression Are Uniformly Elevated in Inflammatory Conditions Depressive syndromes are a risk factor for the development of CAD, metabolic syndrome, cancer Depression increases morbidity in all inflammatory conditions and has been repeatedly shown to increase risk of mortality in context of CAD and cancer (and its treatment) Translational Targets IFN-a Raison, Capuron, Miller. Trends in Immunology. 26;227: PMID:
12 Inflammation and Treatment Resistance Clinical Predictor of Antidepressant Non-Response Obesity Early Life Stress Medical Illness Personality Disorders/Anxiety Relation to Inflammation Dose response relationship between BMI and inflammatory markers Increased inflammation and inflammatory response to stress in individuals exposed to early life stress Increased inflammatory markers in cancer and cardiovascular disease Increased inflammatory markers in patients with Anxiety Disorders, Borderline Personality Disorder and Neuroticism Inflammation and Depression: The Perfect Storm Cytokines and Treatment Resistance Cytokines reduce monoamine synthesis (IDO) and increase reuptake (p38 MAPK) Conventional antidepressants act through increasing the availability of monoamines (block reuptake) Cytokines inhibit neurogenesis Conventional antidepressants are less effective in the absence of neurogenesis 1 Cytokines impact glutamate metabolism Conventional antidepressants target monoamines and do not act on glutamate metabolism Ketamine, a glutamate antagonist, is effective in treatment-resistant depression 2 IDO = indoleamine 2,3 dioxygenase; MAPK = mitogen activated protein kinase 1. Santarelli, et al. Science. 23;31: PMID: aan het Rot M, et al. Biological Psychiatry. 21;67: PMID: Etanercept and Clinical Outcomes, Fatigue, and Depression in Psoriasis Double-Blind Placebo-Controlled Randomized Phase III Trial Improvement in symptoms of depression were not correlated with objective measures of skin clearance or joint pain Tyring S, et al. Lancet. 26;367(954): PMID:
13 Testing the Cytokine Hypothesis of Depression Does blockade of inflammatory cytokines reverse depression in patients with treatment-resistant depression (TRD)? Goal: To Test the Cytokine Hypothesis of Depression in Patients with TRD TNF-alpha Antagonist Scientific Reasons TNF-alpha reliably elevated in MDD TNF-alpha and its soluble receptor correlates with IFN-alpha-induced depression TNF-alpha antagonist improved depressed mood in patients with inflammatory disorders TNF receptor KO mice exhibit antidepressant-like response and decreased anxiety following immune stimulation Goal: To Test the Cytokine Hypothesis of Depression in Patients with TRD (cont d.) TNF-alpha Antagonist Infliximab monoclonal antibody directed at TNF-alpha Used to treat autoimmune and inflammatory disorders Pharmacologic reasons Biologics (monoclonal antibodies) have no off-target effects or drug-drug interactions (directly test the cytokine hypothesis of depression) Limited brain penetrance (central vs. peripheral effects) No compliance issues with infusions Off label use 13
14 Double-Blind, Parallel- Group, Randomized Design TRD Pts (N = 6) INFLIX (5mg/kg) Baseline N = 3 Wk 1 Wk 2 Wk 3 Wk 4 Wk 6 Wk 8 Wk 1 Wk 12 Stratification Male vs. Female CRP >2 vs. CRP 2 Randomization PLACEBO N = 3 INFUSION INFUSION INFUSION Clinician-Administered Psychiatric Assessments (HAM-D, CGI) Adverse Events Evaluation Blood Draw for Inflammatory Markers and Safety Labs Off label use Inclusion/Exclusion Criteria Males/Females ages 25-6 Medically Healthy (Normal PE and labs) MDD or Bipolar depressed by SCID QIDS-16 score 14 On stable antidepressant regimen or off meds for at least 4 weeks No psychotic symptoms or hx of psychosis No substance abuse X 6 months Not suicidal Non-pregnant on birth control Demographic Characteristics of Study Sample Infliximab (n = 3) Placebo (n = 3) Age (yrs.) mean (SD) 42.5 (8.2) 44.3 (9.4) Sex (female) no. (%) 2 (66%) 2 (66%) Ethnic Origin - no. (%) Caucasian Black Other Education (Highest Degree) no. (%) Graduate Degree College Graduate Partial College High School Graduate 23 (77%) 6 (2%) 1 (3%) 8 (27%) 13 (43%) 8 (27%) 1 (3%) 23 (77%) 5 (17%) 2 (6%) 7 (23%) 13 (43%) 9 (3%) 1 (3%) Unemployed no. (%) 12 (4%) 12 (4%) Off label use 14
15 Clinical Characteristics of Study Sample Infiximab Placebo Age of Onset of MDD (yrs.) mean (SD) 19.1 (8.3) 18.9 (1.7) Lifetime Episodes of MDD no. (SD) 8.7 (24.8) 7.8 (24.8) Duration of Current Episode (mos.) mean (SD) (148.8) (165.25) Antidepressant Trials in Current Episode no. (SD) 4.6 (3.2) 3.7 (2.1) MGH-S score mean (SD) 7.73 (6.6) 6.1 (3.5) Family History of MDD no. (%) 27 (9%) 23 (77%) Mood-Relevant Psychotropic Medication no. (%) 16 (53%) 21 (7%) Co-Morbid Medical Illness no. (%) 13 (43%) 19 (63%) Bipolar Disorder no. (%) 3 (1%) 6 (2%) Clinical Characteristics of Study Sample (cont d.) Infiximab Placebo BMI (kg/m2) mean (SD) 31.2 (6.9) 32.7 (8.) Baseline hs-crp (mg/l) mean (SD) 6.21 (9.1) 5.7 (8.1) Baseline HAM-D 17 mean (SD) 24.1 (4.) 23.6 (3.8) Baseline CGI-severity mean (SD) 4.8 (.59) 4.8 (.81) Change in HAM-D-17 in Infliximab vs. Placebo- Treated TRD Patients LS Mean (SEM) Change in HAM- D-17 from Baseline Significant interaction among treatment, time and log hs-crp (t = 2.65, df = 32, p =.1) Off label use 15
16 Change in HAM-D-17 Score from Baseline to Week 12 (Infliximab- Placebo) in TRD Patients Subgrouped By Baseline Plasma hs-crp Off label use Standardized Effect Size =.41 favoring infliximab at CRP > 5mg/L Change in HAM-D-17 Scores from Baseline to Week 12 in Infliximab- or Placebo-Treated TRD Patients with a Baseline CRP > 5 mg/l versus 5mg/L A. CRP > 5mg/L B. CRP 5mg/L Off label use Percent Treatment Responders in Infliximab- vs. Placebo-Treated TRD Patients with a Baseline hs-crp 5mg/L or >5mg/L Treatment Response ( 5 reduction in HAM-D-17 at any point during treatment) Off label use 16
17 Symptoms Responsive to Infliximab and Placebo in TRD Subjects with Baseline hs-crp>5 Off label use Hitting the Sweet Spot Summary Depression is associated with evidence of increased inflammation, which in turn may contribute to the impact of depression on comorbid medical disorders Stress is capable of activating the inflammatory response (likely through SNS pathways) Activation of the inflammatory response can induce behavioral symptoms that overlap with MDD 17
18 1/19/12 Summary (cont d.) Cytokine (IFN-alpha)-induced depression appears to be mediated by alterations in serotonin metabolism, activation of CRH pathways, and alterations in basal ganglia circuitry Aggressive preventative treatment strategies can be used to limit depression in high-risk medically ill Treatments targeting the immune system may be relevant for the treatment of depression in both medically ill and medically healthy patients Co-sponsored by Save the Date! 6th Annual Chair Summit September 26-28, 213 Westin Tampa Harbour Island Tampa, Florida Check out for the most recent information on Chair Summit 213. Registration will be open soon. See you in Tampa! 18
Putting the Brain Back in the Body: A call for integrating physical and mental health
Joint Commission National Quality Approval Putting the Brain Back in the Body: Raymond J. Kotwicki, MD, MPH Chief Medical Officer, Skyland Trail Adjunct Associate Professor, Emory University School of
More informationCharles B. Nemeroff, M.D., Ph.D.
CASE STUDY 1 Charles B. Nemeroff, M.D., Ph.D. Leonard M. Miller Professor and Chairman Department of Psychiatry and Behavioral Sciences Director, Center on Aging University of Miami Miller School of Medicine
More informationCharles B. Nemeroff, M.D., Ph.D.
CASE STUDY 2 Charles B. Nemeroff, M.D., Ph.D. Leonard M. Miller Professor and Chairman Department of Psychiatry and Behavioral Sciences Director, Center on Aging University of Miami Miller School of Medicine
More informationThe Emerging Role of the Immune System in Depression
The Emerging Role of the Immune System in Depression Charles L. Raison, MD Professor, School of Human Ecology Professor, Department of Psychiatry School of Medicine and Public Health University of Wisconsin,
More informationPrediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry
Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry Presented by: Charles B. Nemeroff, M.D., Ph.D. Leonard M. Miller Professor and Chairman
More informationPrediction of Disease Vulnerability and Treatment Response in Mood Disorders: Psychiatry
Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry Presented by: Charles B. Nemeroff, M.D., Ph.D. Leonard M. Miller Professor and Chairman
More informationProgress in Suicide Prevention
Progress in Suicide Prevention Charles B. Nemeroff, M.D., Ph.D. Leonard M. Miller Professor and Chairman Department of Psychiatry and Behavioral Sciences Director, Center on Aging University of Miami,
More informationDiabetes. & Mental Health. David J. Robinson MD, FRCPC. This slide is for review purposes only and not for presentations.
Diabetes This slide is for review purposes only and not for presentations & Mental Health David J. Robinson MD, FRCPC CMHA - London, ON In the past 2 years, I have received speaking honoraria from, and
More informationPrediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry
Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry Presented by: Charles B. Nemeroff, M.D., Ph.D. Leonard M. Miller Professor and Chairman
More information#268 APRIL 2016 Depression is a complex heterogeneous disorder, which may need a similarly heterogeneous offer of treatment
ARE CHRONIC INFLAMMATION AND ITS METABOLIC COUNTERPART, INSULIN RESISTANCE, THE COMMON DENOMINATORS FOR ALL CHRONIC BEHAVIORAL AND NEURODEGENERATIVE DISORDERS? A REVIEW OF THE EVIDENCE PART III THE COMPLICATED
More informationLinda Carpenter, M.D.
Stress, Depression and Physical Health Linda Carpenter, M.D. Associate Professor of Psychiatry and Human Behavior and Medicine Alpert Medical School of Brown University Chief, Butler Hospital Mood Disorders
More informationANXIOUS DEPRESSION. Ned H. Kalin, MD University of Wisconsin Alan F. Schatzberg, MD Stanford University
ANXIOUS DEPRESSION Ned H. Kalin, MD University of Wisconsin Alan F. Schatzberg, MD Stanford University NED H. KALIN, MD Disclosures!! Research/Grants: None!! Speakers Bureau: None!! Consultant: None!!
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationThe Neurobiology of Mood Disorders
The Neurobiology of Mood Disorders J. John Mann, MD Professor of Psychiatry and Radiology Columbia University Chief, Department of Neuroscience, New York State Psychiatric Institute Mood Disorders are
More informationTHE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ
THE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ Disclosures: On National Advisory Boards of: (1) Pfizer Pharmaceuticals (2) MSD (3) Roche Pharmaceuticals (4) Abbott International: AfME Rheumatology
More informationThe Immune System: The Mind Body Connection. Presented by Margaret Kemeny, Ph.D. Department of Psychiatry, University of California, San Francisco
The Immune System: The Mind Body Connection Presented by Margaret Kemeny, Ph.D. Department of Psychiatry, University of California, San Francisco Psychoneuroimmunology Investigation of the bidirectional
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCondensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia
Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia I. Key Points a. Schizophrenia is a chronic illness affecting all aspects of person s life i. Treatment Planning Goals 1.
More informationFrailty and Depression in Late Life
1 Frailty and Depression in Late Life Patrick J. Brown, PH.D Assistant Professor of Clinical Psychology in Psychiatry College of Physicians and Surgeons, Columbia University New York State Psychiatric
More informationThe role of inflammation in depression: from evolutionary imperative to modern treatment target
The role of inflammation in depression: from evolutionary imperative to modern treatment target Andrew Miller, Emory University Charles Raison, Emory University Journal Title: Nature Reviews Immunology
More information11/13/18. MICROBIOME AND THE BRAIN: How your gut impacts wellbeing. Approach. Lessons from Venice. Session One. Sue Langley
MICROBIOME AND THE BRAIN: How your gut impacts wellbeing Session One Sue Langley 2018 2017 Langley Group IP Trust Approach Lessons from Venice 1 Lessons from Venice Agenda 2. Implications and research
More information4/29/2016. Psychosis A final common pathway. Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue
Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue Disclosures Financial relationships with commercial interests Douglas R. Robbins, M.D. Maine Medical Center Tufts University
More informationInflammation in the clinic
Inflammation in the clinic Stephen T. Holgate MRC Clinical Professor of Immunopharmacology ILSI Europe Workshop, Seville, May 14-15 2012 The immune system acts in four general ways to ensure host defence
More informationIncorporating Biologics Into Your Practice
Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationORIGINAL ARTICLE. A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression
ORIGINAL ARTICLE A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression The Role of Baseline Inflammatory Biomarkers Charles L. Raison, MD;
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationFIBROMYALGIA. Leena Mathew, M.D. Director Pain Fellowship Associate Professor Department of Anesthesiology Columbia University
FIBROMYALGIA Leena Mathew, M.D. Director Pain Fellowship Associate Professor Department of Anesthesiology Columbia University disclosures I have no conflicts of interest objectives Be able to accurately
More informationInnate Immunity. Chapter 3. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples. Antimicrobial peptide psoriasin
Chapter Know Differences and Provide Examples Innate Immunity kin and Epithelial Barriers Antimicrobial peptide psoriasin -Activity against Gram (-) E. coli Connection Between Innate and Adaptive Immunity
More informationEli Lilly and Company
Eli Lilly and Company Ixekizumab Phase 2 Psoriasis Data Investment Community Discussion April 10, 2012 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's
More informationΝευροφυσιολογία και Αισθήσεις
Biomedical Imaging & Applied Optics University of Cyprus Νευροφυσιολογία και Αισθήσεις Διάλεξη 19 Ψυχασθένειες (Mental Illness) Introduction Neurology Branch of medicine concerned with the diagnosis and
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationSocial stressors and suicidal behaviour: neurobiology. Philippe Courtet Montpellier
Social stressors and suicidal behaviour: neurobiology Philippe Courtet Montpellier WHO estimates about 1.5 million deaths by suicide per year worldwide by 2020 10-20 fold more suicide attempts (Organisation
More informationQUALIFIER #1 THE SUCCESS OF SSRIs PROVES THAT DEPRESSION IS NOT INFLAMMATORY
ARE CHRONIC INFLAMMATION AND ITS METABOLIC COUNTERPART, INSULIN RESISTANCE, THE COMMON DENOMINATORS FOR ALL CHRONIC BEHAVIORAL AND NEURODEGENERATIVE DISORDERS? A REVIEW OF THE EVIDENCE PART V DEPRESSION
More informationIris Manor, MD. UK Adult ADHD Network 4th Annual Congress London, England September 11, 2014
Metadoxine Extended Release in Adults With Predominantly Inattentive Attention-Deficit/ Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Crossover Trial Disclosures
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More information11/9/2018 LEARNING OBJECTIVES ANXIETY BACKGROUND EPIDEMIOLOGY USE OF CRANIAL ELECTROTHERAPY STIMULATION (ALPHA-STIM) IN ANXIETY
LEARNING OBJECTIVES Explain epidemiology, etiology, and standard of care of anxiety Discuss Alpha-Stim administration, indications, and mechanism of action Analyze primary literature to determine efficacy
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationAttribution: University of Michigan Medical School, Department of Microbiology and Immunology
Attribution: University of Michigan Medical School, Department of Microbiology and Immunology License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution
More informationBiologic agents in Internal Medicine-2018: Targeted therapies for.
Biologic agents in Internal Medicine-2018: Targeted therapies for. Chronic inflammatory diseases affecting the skin Chronic inflammatory diseases affecting the gut Chronic inflammatory diseases affecting
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationA life course approach to understanding sex differences in depression and inflammation in mid-life
A life course approach to understanding sex differences in depression and inflammation in mid-life Natalie Slopen, ScD Assistant Professor Department of Epidemiology and Biostatistics University of Maryland,
More informationIn vivo effect of anti-inflammatory compounds on HIV-1 gp120 -mediated brain inflammation
In vivo effect of anti-inflammatory compounds on HIV-1 gp120 -mediated brain inflammation Tamima Ashraf, PhD candidate Supervisor: Dr. Reina Bendayan University of Toronto, Leslie Dan Faculty of Pharmacy,
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationSupplementary Online Content
Supplementary Online Content Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by Hepatitis C- Associated Depression Ondria C. Gleason, MD, FAPA, FAPM University of Oklahoma School of Community Medicine Tulsa, OK Ondria
More informationRole of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure
ORIGINAL ARTICLE JIACM 2009; 10(1 & 2): 18-22 Abstract Role of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure N Nand*, HK Aggarwal**,
More informationClinical Policy Title: Ketamine for treatment-resistant depression
Clinical Policy Title: Ketamine for treatment-resistant depression Clinical Policy Number: 00.02.13 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: January
More informationDepression and anxiety increase the risk for preterm birth
1 Proinflammatory cytokines rise in last trimester Women s highest risk of depression in the last trimester Cytokines remain elevated postpartum Depression and anxiety increase the risk for preterm birth
More informationC-reactive protein. An ED perspective Greg Stevens May 2010
C-reactive protein An ED perspective Greg Stevens May 2010 Basic Biology Is a short Pentraxin Penta 5, ragos berries 224 residue protein 25106 Da Gene 1q21-q23 q23 History Tillett WS, Francis T Jr. Serological
More informationADHD and Adverse Health Outcomes in Adults
Thomas J. Spencer, MD This work was supported in part by a research grant from Shire (Dr. Spencer) and by the Pediatric Psychopharmacology Council Fund. Disclosures Dr. Spencer receives research support
More informationHyperlipidemia in an Otherwise Healthy 80 Year-Old Patient. Theodore D Fraker, Jr, MD Professor of Medicine
Hyperlipidemia in an Otherwise Healthy Theodore D Fraker, Jr, MD Professor of Medicine Orlando, Florida October 7-9, 2011 80-Year-Old Patient Primary Prevention Issues in the Elderly: Coronary artery disease
More informationClinical Education Initiative INTRODUCTION TO HIV PSYCHIATRY. Speaker: Hansel Arroyo, MD
Clinical Education Initiative Support@ceitraining.org INTRODUCTION TO HIV PSYCHIATRY Speaker: Hansel Arroyo, MD 3/1/2017 Introduction to HIV Psychiatry [video transcript] 00:00:07 - So we're gonna be talking
More informationTNF Inhibitors: Lessons From Immunogenicity
TNF Inhibitors: Lessons From Immunogenicity Edward Keystone, MD, FRCP(C) Professor of Medicine University of Toronto Toronto, Canada Edward Keystone, MD FRCP(C) Disclosures Sources of Funding for Research:
More informationMood Disorders-Major Depression
Mood Disorders Paula Gibbs, MD Assistant Professor Department of Psychiatry Medical Director of 5West Med-Psych University of Utah Hospitals and Clinics Mood Disorders-Major Depression Key Points for Major
More informationThe Role of the Immune System in Translating Early-Life Experience to Later-Life Brain and Behavior
The Role of the Immune System in Translating Early-Life Experience to Later-Life Brain and Behavior STACI D. BILBO DEPARTMENT OF PSYCHOLOGY AND NEUROSCIENCE DUKE UNIVERSITY Thanks to! Dr. Mark Hutchinson
More informationWest Virginia University School of Medicine, Morgantown, West Virginia
MARY CARROLL SHEMO, M.D., D.F.A.P.A. CURRICULUM VITAE Psychiatric Alliance of the Blue Ridge Office: (434) 984-6777 First Floor, Old Ivy Commons, 2496 Old Ivy Road, Suite 400 Fax: (434) 296-1412 22903-4895
More informationPediatric Psoriasis Comorbidities. Kelly M. Cordoro, M.D. Associate Professor of Dermatology and Pediatrics University of California, San Francisco
Pediatric Psoriasis Comorbidities Kelly M. Cordoro, M.D. Associate Professor of Dermatology and Pediatrics University of California, San Francisco log2 (Expression/hARP) Th1 CXCL10 Disclosures * *** **
More informationInnate immunity. Abul K. Abbas University of California San Francisco. FOCiS
1 Innate immunity Abul K. Abbas University of California San Francisco FOCiS 2 Lecture outline Components of innate immunity Recognition of microbes and dead cells Toll Like Receptors NOD Like Receptors/Inflammasome
More informationTGF-ß1 pathway as a new pharmacological target for neuroprotection in AD. Filippo Caraci
Department of Clinical and Molecular Biomedicine Section of Pharmacology and Biochemistry Department of Educational Sciences University of Catania TGF-ß1 pathway as a new pharmacological target for neuroprotection
More informationMental Health: Where Nutrition meets Psychiatry By Nicola Walters, Registered Dietitian
Mental Health: Where Nutrition meets Psychiatry By Nicola Walters, Registered Dietitian Key Focus Areas Overview of Global & SA Statistics Analysis of the Evidence Sugar & Refined Carbohydrates Fat: dietary
More informationEpidemiology of Chronic Fatigue Syndrome (CFS)
Epidemiology of Chronic Fatigue Syndrome (CFS) Elizabeth Maloney, MS, DrPH Chronic Viral Diseases Branch National Center for Zoonotic, Vector-borne and Enteric Diseases Centers for Disease Control and
More informationCognitive Research Corporation
Cognitive Research Corporation Contract Research Organization offering specialized expertise to fit the unique needs of each client Bobbie Theodore clinicaltrials@alliancesites.com An Alliance of Quality
More informationCell-Derived Inflammatory Mediators
Cell-Derived Inflammatory Mediators Introduction about chemical mediators in inflammation Mediators may be Cellular mediators cell-produced or cell-secreted derived from circulating inactive precursors,
More informationInnate Immunity. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples Chapter 3. Antimicrobial peptide psoriasin
Know Differences and Provide Examples Chapter * Innate Immunity * kin and Epithelial Barriers * Antimicrobial peptide psoriasin -Activity against Gram (-) E. coli Connection Between Innate and Adaptive
More informationA Study of Comorbidities and Nutritional Supplements Strongly Associated with Inflammatory Bowel Disease
Alpenglow: Binghamton University Undergraduate Journal of Research and Creative Activity Volume 3 Issue 1 Article 13 4-24-2017 A Study of Comorbidities and Nutritional Supplements Strongly Associated with
More information11/20/18. MICROBIOME AND THE BRAIN: How your gut impacts Wellbeing. Agenda. Session 1 Reminder. Session Two. Sue Langley
MICROBIOME AND THE BRAIN: How your gut impacts Wellbeing Session Two Sue Langley 2018 2017 Langley Group IP Trust Agenda 2. Implications and research 1. Introduction to your microbiome 3. What next? Session
More informationAbdul R. Khan, MD LABORATORY DIRECTOR S. Pioneer Blvd Artesia, CA Tel: Fax: LABORATORY REPORT
Patient Info: Name: DOB: Gender: Phone No: Collection Date: Received Date: Report Date: Age: Abdul R. Khan, MD LABORATORY DIRECTOR 18173 S. Pioneer Blvd Artesia, CA 90701 Tel: 562 924 2299 Fax: 562 924
More informationDepression in Peripheral Artery Disease: An important Predictor of Outcome. Goals. Goals. Marlene Grenon, MD Assistant Professor of Surgery, UCSF
Depression in Peripheral Artery Disease: An important Predictor of Outcome There are no conflicts of interest Marlene Grenon, MD Assistant Professor of Surgery, UCSF UCSF VASCULAR SURGERY SYMPOSIUM SAN
More informationHuman leukocyte antigen (HLA) system
Is HLA a determinant of prognosis or therapeutic response to cytokines, IFN and anti-ctla4 blocking antibodies in melanoma? Helen Gogas, M.D. Ass. Professor in Medical Oncology 1st Department of Medicine,
More informationPharmacological Treatments for Tobacco Users with Behavioral Health Conditions
Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions Jill M Williams, MD Professor Psychiatry Director, Division Addiction Psychiatry Robert Wood Johnson Medical School Disclosures
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationOscar L. Lopez, M.D. Departments of Neurology and Psychiatry Alzheimer s Disease Research Center University of Pittsburgh School of Medicine
14th Annual Mild Cognitive Impairment Symposium The Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center Miami, Florida Markers of inflammation and immune activation, small
More informationJournal Club: The Use of Fish Oil Lipid Emulsion for Gastrointestinal Surgery Patients
S a m m i M o n t a g F i s h O i l E m u l s i o n J o u r n a l C l u b - P a g e 1 Journal Club: The Use of Fish Oil Lipid Emulsion for Gastrointestinal Surgery Patients Introduction/Background I. Surgical
More informationSection on Immunology and Psychiatry Section Newsletter March 1, 2018
Section on Immunology and Psychiatry Section Newsletter March 1, 2018 Neuroprogression in Psychiatric Disorders Angelos Halaris, MD Loyola University Chicago Stritch School of Medicine Brian E. Leonard,
More informationDifferentiating MDD vs. Bipolar Depression In Youth
Differentiating MDD vs. Bipolar Depression In Youth Mai Uchida, M.D. Staff Physician Clinical and Research Programs in Pediatric Psychopharmacology Massachusetts General Hospital Disclosures Neither I
More informationInflammation: How to Cool the Fire Inside your Gut? REINVENTING DIAGNOSTICS
Inflammation: How to Cool the Fire Inside your Gut? REINVENTING DIAGNOSTICS Future of Healthcare REINVENTING DIAGNOSTICS Inflammation Gut Inflammation Basis of a Healthy
More informationTRAUMATIC BRAIN INJURY: FROM PHYSIOLOGY TO TREATMENT Presented by: Dr. J. Brandon Brock, DC, MSN, RN, NP-C, DAAIM, DACNB, BCIM, FICC
TRAUMATIC BRAIN INJURY: FROM PHYSIOLOGY TO TREATMENT Presented by: Dr. J. Brandon Brock, DC, MSN, RN, NP-C, DAAIM, DACNB, BCIM, FICC https://www.facebook.com/drbrandonbrock/ The Problem!!! What are We
More informationCollaborating, Co-managing and Facilitating Metabolic Improvement in Patients with Severe Mental Illness (SMI)
Collaborating, Co-managing and Facilitating Metabolic Improvement in Patients with Severe Mental Illness (SMI) 14 th Canadian Collaborative Mental Health Care Conference Montréal, Québec June 28, 2013
More informationCarlos A. Zarate, Jr., M.D
Performing valid analysis in sex differences and treatment response in depression vs. Multi-modal imaging and psychiatric stress testing: A strategy for translational psychopharmacology in mood disorders
More informationDepression in the Medically Ill
Mayo School of Continuous Professional Development Psychiatry in Medical Settings February 9 th, 2017 Depression in the Medically Ill David Katzelnick, M.D. Professor of Psychiatry, Mayo Clinic College
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationRole of the Brain-Lung Axis in Fatigue
Role of the Brain-Lung Axis in Fatigue Y.S. Prakash, M.D., Ph.D. Professor of Anesthesiology and Physiology Chair, Department of Physiology & BME Mayo Clinic Rochester, Minnesota, USA Fatigue in Chronic
More informationBehavioral implications of the dynamic regulation of microglia: the influence of a day versus a lifetime
Behavioral implications of the dynamic regulation of microglia: the influence of a day versus a lifetime Laura K. Fonken Postdoctoral Fellow University of Colorado March 20, 2017 About me: Research Timeline
More informationCurriculum Vitae, Michael J. Downing, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com PROFESSIONAL AFFILIATIONS: Michael
More informationARGININE VASOPRESSIN (AVP)
ARGININE VASOPRESSIN (AVP) AFFECTS BLOOD PRESSURE AND RENAL WATER REABSORPTION WHAT ELSE DOES IT DO? Michael F. Michelis, M.D., F.A.C.P., F.A.S.N. Director, Division of Nephrology Lenox Hill Hospital,
More informationSupplemental Data. Inclusion/exclusion criteria for major depressive disorder group and healthy control group
1 Supplemental Data Inclusion/exclusion criteria for major depressive disorder group and healthy control group Additional inclusion criteria for the major depressive disorder group were: age of onset of
More informationMETABOLIC SYNDROME, NEUROINFLAMMATION AND COGNITIVE IMPAIRMENT: STATE OF LEVEL OUTPATIENT CLINIC IN ITALY
METABOLIC SYNDROME, NEUROINFLAMMATION AND COGNITIVE IMPAIRMENT: STATE OF THE ART AND DATA FROM A SECOND LEVEL OUTPATIENT CLINIC IN ITALY Valeria Calsolaro Post graduating school on Geriatric medicine University
More informationDevelopment of sickness symptoms related to inflammatory response during aggressive cancer therapy
Development of sickness symptoms related to inflammatory response during aggressive cancer therapy Xin Shelley Wang, MD, MPH Charles S. Cleeland, PhD Department of Symptom Research The University of Texas
More informationNOVEL INDICATIONS: Experiences from a Study in MDD with Mixed Features (Mixed Depression)
NOVEL INDICATIONS: Experiences from a Study in MDD with Mixed Features (Mixed Depression) 11 APRIL 2013 Josephine Cucchiaro, PhD Vice President Clinical Operations & Project Management Sunovion Pharmaceuticals
More informationare associated with sickle cell disease and carriers: a study of patients from the southeastregion of Iran
CXC chemokines CXCL1, CXCL9, CXCL10 and CXCL12 are associated with sickle cell disease and carriers: a study of patients from the southeastregion of Iran Mojgan Noroozi Karimabad Molecular Medicine Research
More informationEuroPRevent 2010 Prevention in Adults: Is it good to Know? No conflict of interest to be disclosured
EuroPRevent 2010 Prevention in Adults: Is it good to Know? Almir Sérgio Ferraz MD, PhD Cardiovascular Rehabilitation Center almirferraz@uol.com.br Institute Dante Pazzanese of Cardiology 1 No conflict
More informationChronic Hepatitis C. Risk Factors
Chronic Hepatitis C The hepatitis C virus is one of the most important causes of chronic liver disease in the United States. Almost 4 million Americans or 1.8 percent of the U.S. population have an antibody
More informationMicroglia preconditioning (priming) in central nervous system pathologies
Microglia preconditioning (priming) in central nervous system pathologies Florence Perrin florence.perrin@umontpellier.fr Montpellier, October 2018 1 Spanish anatomists Glia = glue in Greek Santiago Ramon
More informationAnimal Models to Understand Immunity
Animal Models to Understand Immunity Hussein El Saghire hesaghir@sckcen.be Innate Adaptive immunity Immunity MAPK and NF-kB TLR pathways receptors Fast Slow Non-specific Specific NOD-like receptors T-cell
More informationPremium Specialty: Pediatrics
Premium Specialty: Pediatrics Credentialed Specialties include: Adolescent Medicine, Pediatric Adolescent, and Pediatrics This document is designed to be used in conjunction with the UnitedHealth Premium
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
More informationAging with Bipolar Disorder. Neha Jain, MD, FAPA Assistant Professor of Psychiatry, UConn Health
Aging with Bipolar Disorder Neha Jain, MD, FAPA Assistant Professor of Psychiatry, UConn Health Objectives Define bipolar disorder in the elderly Review comorbidities How does it differ from bipolar in
More informationEvolve180 / Ideal Northwest Health Profile
Evolve180 / Ideal Northwest Health Profile ABOUT YOU First Name: Last Name: Address: City: State: Zip: Phone: Email: Date of Birth: Age: Height: Occupation: How did you find out about our program? Marital
More information